{"id":408190,"date":"2026-01-14T07:52:10","date_gmt":"2026-01-14T07:52:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/408190\/"},"modified":"2026-01-14T07:52:10","modified_gmt":"2026-01-14T07:52:10","slug":"first-leukaemia-patient-to-receive-pioneering-treatment-on-nhs-says-it-is-very-sci-fi","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/408190\/","title":{"rendered":"First leukaemia patient to receive pioneering treatment on NHS says it is ‘very sci-fi’"},"content":{"rendered":"

The first leukaemia patient to receive a breakthrough treatment since it was made available on the NHS has said it was “fantastic” and “very sci-fi”.<\/p>\n

Oscar Murphy, 28, who has an aggressive form of the blood cancer, was given the “living drug”, called CAR-T therapy, at Manchester Royal Infirmary.<\/p>\n

BBC News was present on 2 January when Oscar received the first of two infusions of his own immune cells, which had been genetically modified to recognise and target his cancer.<\/p>\n

NHS England has agreed to fund the immunotherapy at several centres across the country. About 50 NHS patients a year are likely to benefit from it.<\/p>\n

Oscar was diagnosed with B-cell acute lymphoblastic leukaemia (B-cell ALL) in March 2025.<\/p>\n

He underwent chemotherapy and a donor stem cell transplant in July but in November was told that his cancer had returned.<\/p>\n

“The leukaemia I’ve got is so fast-acting,” the car salesman from Bury said. “It needs an even quicker response to stop it. And we’ve now got an answer for that.”<\/p>\n

In a clinical trial, 77% of patients went into remission<\/a> after treatment, with half showing no signs of cancer after three and a half years.<\/p>\n

On average, the treatment gave patients 15.6 additional months of life.<\/p>\n

Oscar’s haematologist, Dr Eleni Tholouli, said the CAR-T therapy was safer than existing treatments, with fewer side-effects and much more effective.<\/p>\n

“Usually, this type of leukaemia is very aggressive and adult patients don’t live beyond six to eight months. With this therapy, we are able to offer them years and potentially a cure.<\/p>\n

“It’s very significant and is revolutionising the way we tackle this cancer.”<\/p>\n

CAR-T therapy has been available on the NHS for several years for certain types of leukaemia and lymphoma but has only now been extended to adults with B-cell ALL.<\/p>\n

Last month, Oscar had T-cells – a type of white blood cell – removed and sent to a lab in Stevenage.<\/p>\n

The cells were then reprogrammed using a harmless virus to introduce a genetic sequence that enables them to identify the cancer.<\/p>\n

New surface receptors can then recognise and are able to attach to cancer cells – like a lock and key – and mark them for destruction.<\/p>\n

They become “chimeric antigen receptor T-cells” – or CAR T-cells – and their numbers are greatly expanded in the lab to make millions of copies.<\/p>\n

Oscar’s personalised treatment, or living drug, was cryopreserved and sent to Manchester Royal Infirmary.<\/p>\n

The tiny bag containing Oscar’s personalised treatment held 100 million CAR T-cells in just three teaspoons of liquid, and it took only a few minutes to infuse into his bloodstream.<\/p>\n

\"A<\/p>\n

[BBC]<\/p>\n

Oscar said he was surprised the treatment could pack such a powerful punch in such a small dose.<\/p>\n

“It’s very sci-fi, but if it means it gets rid of the cancer permanently and my own cells can do it it’s just fantastic.”<\/p>\n

Oscar had a second infusion of 300 million cells yesterday, marking the end of his CAR-T treatment.<\/p>\n

As this is a “living drug”, the cancer-killing T-cells stay in the body for a long time and will continue to grow and work inside the patient after the final infusion.<\/p>\n

The CAR-T therapy is manufactured by Autolus, a spin-out company from University College London.<\/p>\n

During clinical trials, the patient’s cells had to be sent to laboratories in the US.<\/p>\n

The list price of the treatment is \u00a3372,000 per infusion<\/a>, but the NHS has a confidential discount.<\/p>\n

It will be available to patients over the age of 26 whose B-cell ALL has not responded to treatment or has returned at several centres in England, including Cambridge, Newcastle, Sheffield, Plymouth and London.<\/p>\n

Patients from Wales and Northern Ireland will need to travel to England for treatment. It has not yet been approved in Scotland.<\/p>\n

NHS England estimates that around 50 patients a year may benefit, but Tholouli told the BBC she believed it could be more, and predicted it would eventually be used as a first-line treatment instead of stem cell transplantation.<\/p>\n

Prof Peter Johnson, NHS National Clinical Director for Cancer, said it was a “landmark moment” for people with aggressive blood cancer.<\/p>\n

He added it was “remarkable” the treatment now delivered at NHS centres had been developed from scientific research within the UK.<\/p>\n

“It will help more people like Oscar live longer and healthier lives.”<\/p>\n

\"A<\/p>\n

Chris Williams had the treatment during its experimental phase and has been in remission for nearly three years [BBC]<\/p>\n

Chris Williams, 29, from Belfast was diagnosed with the same aggressive type of leukaemia as Oscar in 2021.<\/p>\n

When the cancer returned, he was given the CAR-T therapy in Manchester when it was still an experimental treatment. He has now been in remission for nearly three years.<\/p>\n

“A few years ago I was very unwell and now I’m able to live a full life. I was able to go back to work. I also met Chloe and now we’re engaged.<\/p>\n

“I have fantastic support from my family and they are over the moon.”<\/p>\n

Oscar and his fiance Lauren were married at Manchester Royal Infirmary last month.<\/p>\n

He told the BBC he wanted to “get it done” because of the uncertainties surrounding his condition, but the couple have another ceremony booked for October.<\/p>\n

“I want children and the white picket fence with my amazing wife – I just want that normality. This is my gateway to doing it and I can’t wait.”<\/p>\n","protected":false},"excerpt":{"rendered":"The first leukaemia patient to receive a breakthrough treatment since it was made available on the NHS has…\n","protected":false},"author":2,"featured_media":408191,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[171970,63776,171968,49,48,7714,39373,84,171969,171967,36717,171971,82940,19970],"class_list":{"0":"post-408190","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-acute-lymphoblastic-leukaemia","9":"tag-blood-cancer","10":"tag-breakthrough-treatment","11":"tag-ca","12":"tag-canada","13":"tag-cancer","14":"tag-cancer-cells","15":"tag-health","16":"tag-immune-cells","17":"tag-manchester-royal-infirmary","18":"tag-nhs-england","19":"tag-nhs-patients","20":"tag-stem-cell-transplant","21":"tag-therapy"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/408190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=408190"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/408190\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/408191"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=408190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=408190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=408190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}